REAL LIFE DATA OF CHRONIC MYELOID LEUKEMIA PATIENTS IN ISPARTA

Abstract

Objective
 Chronic myeloid leukemia is a myeloproliferative
 neoplasm with an incidence of 1–2 cases per 100
 000 adults. Central to the pathogenesis of CML, is the
 fusion of the Abelson murine leukemia (ABL1) gene
 on chromosome 9 with the breakpoint cluster region
 (BCR) gene on chromosome 22. The therapeutic
 landscape changed dramatically with the development
 of the tyrosine kinase inhibitors (TKIs). This “targeted”
 approach altered the natural history of CML, improving
 the 10-year survival rate to 80-90%. This study aims to
 investigate the effective management of TKI treatment
 and overall survival in “real-life” CML patients and to
 discuss the results with current literature.
 Material and Method
 Fifty-eight patients who were diagnosed as CML
 between 2000 and 2018 in Suleyman Demirel
 University Hematology Department were evaluated.
 Patients’ clinical and laboratory characteristics, clinical
 and demographical features, treatment options, side
 effects and responses were evaluated in this study.
 Risk assessment and staging applied with World Health
 Organization criteria and Sokal Hasford and Eutos
 risk scoring system. We determined hematological,
 cytogenetic and molecular response according to
 European Leukemia Network criteria.
 Results
 The average age, male / female ratio and survival
 rates were found similar to those in literature. The
 age distribution (p = 0,001) and Charlson comorbidity
 index (p = 0.005) and Charlson comorbidity-age index
 (p = 0,000) had a statistically significant effect on
 overall survival. Age distribution (p = 0,029), Charlson
 comorbidity age index (p = 0,001) and major molecular
 response at 12 months (p = 0,028) were found to have
 a significant effect on disease-free survival. Major
 molecular response at 12 months (p = 0,006) also
 had a statistically significant effect on progression-free
 survival. Reticular fiber grade did not significantly affect
 overall survival, disease-free survival and progressionfree
 survival of patients.
 Conclusion
 These results suggest that CML is generally well
 managed with existing treatment options and that
 death occur more frequently due to other medical
 problems. In CML, Charlson indices have been shown
 to be significantly associated with overall survival and
 disease-free survival.